Fecal Microbiota Transplant for Relapsing Clostridium difficile Infection Using a Frozen Inoculum From Unrelated Donors: A Randomized, Open-Label, Controlled Pilot Study
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Recurrent Clostridium difficile infection (CDI) with poor response to standard antimicrobial therapy is a growing medical concern. We aimed to investigate the outcomes of fecal microbiota transplant (FMT) for relapsing CDI using a frozen suspension from unrelated donors, comparing colonoscopic and nasogastric tube (NGT) administration. METHODS: Healthy volunteer donors were screened and a frozen fecal suspension was generated. Patients with relapsing/refractory CDI were randomized to receive an infusion of donor stools by colonoscopy or NGT. The primary endpoint was clinical resolution of diarrhea without relapse after 8 weeks. The secondary endpoint was self-reported health score using standardized questionnaires. RESULTS: A total of 20 patients were enrolled, 10 in each treatment arm. Patients had a median of 4 (range, 2-16) relapses prior to study enrollment, with 5 (range, 3-15) antibiotic treatment failures. Resolution of diarrhea was achieved in 14 patients (70%) after a single FMT (8 of 10 in the colonoscopy group and 6 of 10 in the NGT group). Five patients were retreated, with 4 obtaining cure, resulting in an overall cure rate of 90%. Daily number of bowel movements changed from a median of 7 (interquartile range [IQR], 5-10) the day prior to FMT to 2 (IQR, 1-2) after the infusion. Self-ranked health score improved significantly, from a median of 4 (IQR, 2-6) before transplant to 8 (IQR, 5-9) after transplant. No serious or unexpected adverse events occurred. CONCLUSIONS: In our initial feasibility study, FMT using a frozen inoculum from unrelated donors is effective in treating relapsing CDI. NGT administration appears to be as effective as colonoscopic administration. CLINICAL TRIALS REGISTRATION: NCT01704937.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a pilot open-label randomized trial, frozen FMT by nasogastric tube appeared to be as effective as colonoscopic administration in resolving CDIassociated diarrhea. 126”
From Key determinants of success in fecal microbiota transplantation: From microbiome to clinic (2023) · cites this paper as [126]
In the citing paper
“Youngster et al. conducted a randomized pilot study comparing upper and lower GI routes of FMT, and the report found a non-significant difference in cure rate between the two different administration methods.67”
From Fecal microbiota transplantation: Review and update (2019) · cites this paper as [67]
In the citing paper
“FMT has been examined in both young and old, patients with limited comorbidities as well as those considered to be immunocompromised,43 and the procedure has been shown to be safe, well-tolerated, and effective.”
From Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook (2015) · cites this paper as [43]
In the citing paper
“Furthermore, flares of FMT in patients with both UC and CD have been described,43, 75, 76 raising important questions around safety and the potential to worsen disease in some patients.”
From Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook (2015) · cites this paper as [43]
In the citing paper
“These include complications of endoscopy, such as perforation and bleeding, and side effects related to sedation, such as aspiration43.”
From Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook (2015) · cites this paper as [43]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Ultra-high-throughput microbial community analysis on the Illumina HiSeq and MiSeq platforms
Caporaso, J. G., Lauber, C. L., Walters, W. A., Berg-Lyons, D., Huntley, J., Fierer, N., Owens, S. M., Betley, J., Fraser, L., Bauer, M., et al. (2012) · The ISME Journal · doi:10.1038/ismej.2012.8 · Cited by 8,839 · cited 1×
“DNA was extracted and the V4 region of the 16S gene was sequenced using an Illumina MiSeq (Illumina, San Diego, CA) as described previously [30].”
MethodDuodenal Infusion of Donor Feces for Recurrent Clostridium difficile
van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F. W. M., Tijssen, J. G. P., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205037 · Cited by 3,708
TROTTI, A., COLEVAS, A., SETSER, A., RUSCH, V, JAQUES, D., BUDACH, V, LANGER, C., MURPHY, B., CUMBERLIN, R., & COLEMAN, C. (2003) · Seminars in Radiation Oncology · doi:10.1016/s1053-4296(03)00031-6 · Cited by 2,569 · cited 1×
“0 [26] approved by the FDA and institutional review board (IRB).”
BackgroundFidaxomicin versus Vancomycin for Clostridium difficile Infection
Louie, T. J., Miller, M. A., Mullane, K. M., Weiss, K., Lentnek, A., Golan, Y., Gorbach, S., Sears, P., & Shue, Y.-K. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa0910812 · Cited by 1,585 · cited 1×
“recurrence exceeds 60% with antimicrobial therapy [3, 5–8].”
BackgroundClostridium difficile infection: new developments in epidemiology and pathogenesis
Rupnik, M., Wilcox, M. H., & Gerding, D. N. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2164 · Cited by 1,380 · cited 1×
“The emergence of a virulent strain of the organism (NAP1/BI/027) has been associated with even higher rates of treatment failure [9,10].”
BackgroundClostridium difficile— More Difficult Than Ever
Kelly, C. P., & LaMont, J. T. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0707500 · Cited by 1,313 · cited 1×
“In the United States the incidence of CDI has tripled over the last 15 years [3].”
BackgroundDecreased Diversity of the Fecal Microbiome in Recurrent Clostridium difficile–Associated Diarrhea
Chang, J. Y., Antonopoulos, D. A., Kalra, A., Tonelli, A., Khalife, W. T., Schmidt, T. M., & Young, V. B. (2008) · The Journal of Infectious Diseases · doi:10.1086/525047 · Cited by 1,010 · cited 1×
“Failure to reconstitute normal flora was shown to be a factor in severe, recurrent, and prolonged illness [13].”
BackgroundTreating Clostridium difficile infection with fecal microbiota transplantation
Bakken, J. S., Borody, T., Brandt, L. J., Brill, J. V., Demarco, D. C., Franzos, M. A., Kelly, C., Khoruts, A., Louie, T., Martinelli, L. P., et al. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.08.014 · Cited by 1,003 · cited 1×
“5 guidelines [26] by a relapse of CDI after having at least three episodes of mild-to-moderate CDI and failure of a 6-8 week taper with vancomycin with or without an alternative antibiotic, OR, at least two episodes of severe CDI resulting in hospitalization and associated with significant morbidity.”
BackgroundSelf-citationKassam, Z., Lee, C. H., Yuan, Y., & Hunt, R. H. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.59 · Cited by 904 · cited 1×
“Another inhibiting factor is the fact that the available data are mostly based on retrospective case series and include only a single randomized trial [21,24,25] to date, making practitioners cautious about adopting FMT as a viable treatment alternative.”
BackgroundHamilton, M. J., Weingarden, A. R., Sadowsky, M. J., & Khoruts, A. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.482 · Cited by 738 · cited 1×
“The work of Hamilton and Khoruts [28] was used as a guide for fecal manipulation, with the exception that all processes were carried out under ambient air, not nitrogen.”
Method
Research works printed but not linked: 1
- 2013, Clostridium difficile infection in children, JAMA Pediatr, 167, 567, 10.1001/jamapediatrics.2013.441 · DOI · Paper page
Cited by
Items 401–500 of 500
Clostridium Difficile Infections: Epidemiology, Diagnosis, and Treatment
McFarland, L. V., Surawicz, C. M., & Vindigni, S. M. (2019) · Wiley eBooks · doi:10.1002/9781119211419.ch19 · Cited by 1
Circuit pharmaceutique, transplantation de microbiote fécal : Des pratiques hétérogènes
Martel, B., & Saint‐Lorant, G. (2019) · Annales Pharmaceutiques Françaises · doi:10.1016/j.pharma.2019.06.001 · Cited by 1
Guseinova, R. M., & Shestakova, E. A. (2022) · Obesity and metabolism · doi:10.14341/omet12901 · Cited by 1
Clinical Utility and Alterations in Bacterial Flora in Fecal Microbiome Transplantation
Dave, A. A., & Robson, R. L. (2015) · International Journal of Medical Students · doi:10.5195/ijms.2015.135 · Cited by 1
“Associations of fecal transplantation with clinical outcomes The clinical variables by the papers reviewed examined age, sex, immune status, antibiotic regimen, CDI recurrence, gastric acid suppression therapy, and patient perception of treatment.(3,10,13-16,18,24) Surprisingly, no correlation of FMT outcomes and vari…”
MethodInfluentialWriters, A. M. (2016) · Drugs & Therapy Perspectives · doi:10.1007/s40267-016-0279-4 · Cited by 1
Tiburcio, Á., Ruiz, H., & Reyes-López, P. A. (2019) · Open Journal of Bacteriology · doi:10.17352/ojb.000010 · Cited by 1
Fecal Transplant: How an Ancient Therapy Is Finding a New Use in Today’s Antibiotic-Resistant Era
McBeth, A., & Dobner, P. (2019) · Journal of Restorative Medicine · doi:10.14200/jrm.2019.0117 · Cited by 1
“One of the first studies to determine efficacy of stored, frozen stool revealed an overall cure rate for rCDI of 90%.(43) Another study conducted in 2014 consisting of 23 recipients of frozen FMT versus 15 receiving fresh FMT revealed an 88% cure rate at 1-year follow-up for both groups.”
BackgroundFecal microbiota transplantation for treatment of irritable bowel syndrome
Halkjær, S. I., Lo, B. Z. S., Cold, F., Christensen, A. H., Gluud, L. L., & Petersen, A. M. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013602 · Cited by 1
[Faecal microbiota transplantation for the treatment of bowel disease].
Rode, A. A., Chehri, M., Petersen, A. M., & Bytzer, P. M. (2017) · Research at the University of Copenhagen (University of Copenhagen) · Cited by 1
Blagonravova, A. S., Zhilyaeva, T. V., & Kvashnina, D. V. (2021) · Journal of microbiology epidemiology immunobiology · doi:10.36233/0372-9311-84 · Cited by 1
Malygina, D., Alexander, V., Olga, Z., Vorobyova, O., Dmitry, P., Daria, Z., & Anna, B. (2022) · Journal of Applied Pharmaceutical Science · doi:10.7324/japs.2021.120201 · Cited by 1
Transplantation de microbiote fécal : de l’évidence aux réalités du terrain
Ballif, A., Gerber, S., Carrez, L., Audry, M., Sadeghipour, F., Mitouassiwou, A., Croxatto, A., Opota, O., Prod’hom, G., Henchoz, S., et al. (2021) · JMIG · doi:10.53738/revmed.2021.17.734.0726 · Cited by 1
Gut Microbiome and Diet: Promising Approach for Treatment of Cognitive Impairment
Soni, A., Gupta, P., & Verma, A. (2022) · Nutritional neurosciences · doi:10.1007/978-981-19-4530-4_12 · Cited by 1
(2022) · Medical & Clinical Research · doi:10.33140/mcr.07.12.07 · Cited by 1
Miguel, A. (2023) · British Journal of Nursing · doi:10.12968/bjon.2023.32.12.546 · Cited by 1
de Carvalho, C. K. L., Dalmedico, M. M., Ioshii, S. O., & Fernandes, B. L. (2024) · Contribuciones a las Ciencias Sociales · doi:10.55905/revconv.17n.1-505 · Cited by 1
Toxin Inhibitors for the Treatment of Clostridium difficile Infection
Ivarsson, M. E. (2014) · Repository for Publications and Research Data (ETH Zurich) · doi:10.3929/ethz-a-010345630 · Cited by 1
Mihaljevic, J. R. (2014) · CU Scholar (University of Colorado Boulder) · Cited by 1
Kwak, S., Choi, J., Hink, T., Reske, K. A., Blount, K., Jones, C., Bost, M. H., Sun, X., Burnham, C. D., Dubberke, E. R., et al. (2020) · doi:10.21203/rs.3.rs-17152/v1 · Cited by 1
Beedles, M. (2015) · CommonKnowledge Research Repository (Pacific University Oregon)
GUT in FOCUS Symposium NOBEL FORUM, Karolinska Institutet
(2015) · Microbial Ecology in Health and Disease · doi:10.3402/mehd.v26.28480
Clostridium difficile Infection Update for the Hospital-Based Physician
Pawlowski, S. W. (2014) · Current Emergency and Hospital Medicine Reports · doi:10.1007/s40138-014-0053-7
“fecal inocula for instillation, and stool substitute preparations of purified intestinal bacteria [76–78].”
BackgroundCurry, S. R., Surawicz, C. M., Binion, D. G., & Brandt, L. J. (2014) · The American Journal of Gastroenterology · doi:10.1038/ajg.2014.229
Overview of the Management Of Clostridium difficile
Ray, A., & Rivera, K. R. (2014)
The microbiome and its therapeutic potential in inflammatory bowel diseases
Rossen, N. (2016) · UvA-DARE (University of Amsterdam)
Fecal microbiota transplantation: Literature review
Stafford, R. E. (2016) · Journal of Nursing Education and Practice · doi:10.5430/jnep.v6n6p79
“[2, 3] In 2007, a new strain,”
Fecal Microbiota Transplantation: Harnessing the Gut Microbiota to Treat Disease
Ziud, H., Bakow, B. R., & Kelly, C. R. (2015) · Microbe Magazine · doi:10.1128/microbe.10.426.1
The Intestinal Microbiome, the Immune System and Spondyloarthropathy
Costello, M., & Brown, M. A. (2017) · Springer eBooks · doi:10.1007/978-3-319-42252-7_8
The epidemiology of Clostridium difficile infection in Australia
Furuya‐Kanamori, L. (2016) · ANU Open Research (Australian National University) · doi:10.25911/5d74e87cda031
Mullane, K. M. (2017) · Springer eBooks · doi:10.1007/978-3-319-64906-1_44
Fecal microbiota transplantation: a case study presentation and educational opportunity
Schmidt, J. D. (2017) · Montana State University ScholarWorks (Montana State University)
Chung, S. H. (2017) · Korean Journal of Gastroenterology · doi:10.4166/kjg.2017.70.5.269
“감염의 치료에 있어서 바로 준비된 세균총과 임상적으로 동등 하였다.(2-4) 또한 대장 내시경을 통해 이루어진 세균총 이식 방 법과 비교하여 볼 때 공여자의 세균총의 동력학 측면에서 차 이가 없었다.”
Infeção por Clostridium difficile - a nossa realidade
Rocha, D. L. M. (2017) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/emf3-n070
Erkek Ürogenital Hastalıkları ve Mikrobiyota
Keleş, İ. (2017) · JOURNAL OF BIOTECHNOLOGY AND STRATEGIC HEALTH RESEARCH
Prather, C. P., Koroma-Nelson, M., & Коган, М. И. (2017) · Oxford University Press eBooks · doi:10.1093/med/9780190466268.003.0017
FECAL MICROBIOTA THERAPY AND ITS POTENTIAL IN MEDICAL PRACTICE
Hašková, K., Dyrhonová, M., & Boštíková, V. (2016) · Military Medical Science Letters · doi:10.31482/mmsl.2016.020
Fecal transplant is superior to oral vancomycin for treatment of recurrent Clostridium difficile
Weber, K. (2018) · Clinical Research in Practice The Journal of Team Hippocrates · doi:10.22237/crp/1536883500
Steinberg, R. (2016) · The Science Journal of the Lander College of Arts and Sciences
Modern approach to the therapy of infections caused by Clostridium difficile
Jaćović, S., Milisavljevic, S. S., Milosavljević, M. N., Јаnkovic, S., & Stefanović, S. (2018) · Racionalna terapija · doi:10.5937/racter10-18509
Molecular Characterization and Moxifloxacin Susceptibility of Clostridium difficile
Mizrahi, S., Hamo, Z., Azrad, M., & Peretz, A. (2019) · Antibiotics · doi:10.3390/antibiotics8030118
“In severe and recurrent cases, fecal microbiota transplantation (FMT) that restores the normal fecal microbiota is efficient [21].”
BackgroundA multidimensional approach towards studying recurrent Clostridium difficile infection
Pickering, D. S. (2019) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York)
Summers, B. D. (2019) · Digital Commons - PCOM (Philadelphia College of Osteopathic Medicine)
FECAL MICROBIOTA TRANSPLANTATION IN ADULTS AS A MODERN FORM OF PAST “COPROTHERAPY”: HOPE OR HYPE?
Ksiądzyna, D. (2020) · Acta Poloniae Pharmaceutica - Drug Research · doi:10.32383/appdr/122149
Another Step in the Journey—From Feces to Regulated Microbial Therapeutics
Youngster, I. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1435
Self-citationNiergarth, J. (2020) · The Atrium (University of Guelph)
Normington, C. (2020) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York)
The hardware method of biomaterial preparation for fecal transplantation
Shedoeva, L. R., Chashkova, E. Y., Геннадьевна, К. О., & Kogan, G. Y. (2020) · Almanac of Clinical Medicine · doi:10.18786/2072-0505-2020-48-060
Applications of Fecal Microbiota Transplantation: Emphasis on Clostridioides difficile Infections
Signorette, J. P., de Oliveira, R. T. D., Montiel, J. M., & Longo, P. L. (2021) · International Journal of Nutrology · doi:10.1055/s-0040-1718996
Gut Microbial Dysbiosis and Cardiovascular Diseases
Gasmi, A., Noor, S., Piscopo, S., & Berthouze, S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819265-8.00050-4
Bircher, L. (2018) · Repository for Publications and Research Data (ETH Zurich) · doi:10.3929/ethz-b-000337725
Çocuk Hastalara Uygulanan Fekal Mikrobiyota Transplantasyonuna Yönelik Hemşirelik Yaklaşımı
Tuğba, D. E. D. E., & İncekar, M. Ç. (2021) · Yüksek İhtisas Üniversitesi Sağlık Bilimleri Dergisi · doi:10.51261/yiu.2021.00039
Otter, J. A. (2014) · Journal of Hospital Infection · doi:10.1016/j.jhin.2014.06.001
“It is tempting to speculate that the OXA-48-carbapenemase was shared between the two clones, representing an ‘outbreak of resistance’.16 Infection Control and Hospital Epidemiology published two updated guidelines for surgical site infection and CDI.17,18 The CDI guideline upholds the surprising recommendation for soa…”
Dupont, A. W., & Khurana, S. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.735582049.793579217
Dupont, A. W., & Khurana, S. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.732670634.793579191
Borenstein, E., & Muller, E. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.732223689.793566912
Research Progress of Gut Microbiota’s Function in Metabolic and Immunological Diseases
孙, 卓. (2022) · Open Journal of Natural Science · doi:10.12677/ojns.2022.106107
Clostridioides(Clostridium)difficile 感染症診療ガイドライン
國島, 広., 大毛, 宏., 鈴木, 広., 中村, 敦., 松元, 一., 三鴨, 廣., 森, 伸., 森永, 芳., 栁原, 克., 山岸, 由., et al. (2018) · Kansenshogaku zasshi · doi:10.11150/kansenshogakuzasshi.92.819
Clostridioides(Clostridium)difficile 感染症診療ガイドライン
國島, 広., 大毛, 宏., 鈴木, 広., 中村, 敦., 松元, 一., 三鴨, 廣., 森, 伸., 森永, 芳., 栁原, 克., & 吉澤, 定. (2020) · Kansenshogaku zasshi · doi:10.11150/kansenshogakuzasshi.94.1
The Japanese Clinical Practice Guidelines for Management of Clostridioides difficile infections 2022
國島, 広., 大毛, 宏., 鈴木, 広., 中村, 敦., 松元, 一., 三鴨, 廣., 森, 伸., 森永, 芳., 栁原, 克., 山岸, 由., et al. (2023) · Kansenshogaku zasshi · doi:10.11150/kansenshogakuzasshi.s1-96
Multiobjective Nonlinear Model Predictive Control of the Microbial Process
Sridhar, L. N. (2023) · Archives of Clinical and Medical Microbiology · doi:10.33140/acmmj.02.02.04
“The microbiome plays a significant role in several human diseases [30-35].”
BackgroundFecal Microbiota Transplantation
Singh, B., Mal, G., Kalra, R. S., & Marotta, F. (2024) · Springer eBooks · doi:10.1007/978-3-031-65459-6_36
Potential Advantages of Pharmaceutical Technology in the Preparation of Faecal Microbial Transplant
Fülöpová, N., Chomová, N., & Franc, A. (2025) · Chemické listy · doi:10.54779/chl20250171
A Clostridioides difficile-fertőzés és kezelése
Dembrovszky, F. (2025) · Magyar Tudomány · doi:10.1556/2065.186.2025.4.19
Les hépatopathies stéatosiques non alcooliques et le microbiote intestinal
Buffet, C., & Buffet, C. (2015) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(15)30078-x
Wilson, B. C., Vatanen, T., Jayasinghe, T. N., Leong, K. S. W., Derraik, J. G., Albert, B. B., Chiavaroli, V., Svirskis, D. M., Beck, K. L., Conlon, C. A., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14594448
Wilson, B. C., Vatanen, T., Jayasinghe, T. N., Leong, K. S. W., Derraik, J. G., Albert, B. B., Chiavaroli, V., Svirskis, D. M., Beck, K. L., Conlon, C. A., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14594445
Long, A. E., Pitta, D., Hennessy, M. L., Indugu, N., Vecchiarelli, B., Luethy, D., Aceto, H. W., & Hurcombe, S. D. A. (2024) · Figshare · doi:10.6084/m9.figshare.26747492
Long, A. E., Pitta, D., Hennessy, M. L., Indugu, N., Vecchiarelli, B., Luethy, D., Aceto, H. W., & Hurcombe, S. D. A. (2024) · Figshare · doi:10.6084/m9.figshare.26747486
Long, A. E., Pitta, D., Hennessy, M. L., Indugu, N., Vecchiarelli, B., Luethy, D., Aceto, H. W., & Hurcombe, S. D. A. (2024) · Figshare · doi:10.6084/m9.figshare.26747510
Wilson, B. C., Vatanen, T., Jayasinghe, T. N., Leong, K. S. W., Derraik, J. G., Albert, B. B., Chiavaroli, V., Svirskis, D. M., Beck, K. L., Conlon, C. A., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14594451
Long, A. E., Pitta, D., Hennessy, M. L., Indugu, N., Vecchiarelli, B., Luethy, D., Aceto, H. W., & Hurcombe, S. D. A. (2024) · Figshare · doi:10.6084/m9.figshare.26241298
Long, A. E., Pitta, D., Hennessy, M. L., Indugu, N., Vecchiarelli, B., Luethy, D., Aceto, H. W., & Hurcombe, S. D. A. (2024) · Figshare · doi:10.6084/m9.figshare.26747507
Long, A. E., Pitta, D., Hennessy, M. L., Indugu, N., Vecchiarelli, B., Luethy, D., Aceto, H. W., & Hurcombe, S. D. A. (2024) · Figshare · doi:10.6084/m9.figshare.26747501
Long, A. E., Pitta, D., Hennessy, M. L., Indugu, N., Vecchiarelli, B., Luethy, D., Aceto, H. W., & Hurcombe, S. D. A. (2024) · Figshare · doi:10.6084/m9.figshare.26747513
Dörfel, P.-N. (2023) · Common Library Network (Der Gemeinsame Bibliotheksverbund) · doi:10.22032/dbt.61839
Long, A. E., Pitta, D., Hennessy, M. L., Indugu, N., Vecchiarelli, B., Luethy, D., Aceto, H. W., & Hurcombe, S. D. A. (2024) · Figshare · doi:10.6084/m9.figshare.26747498
Long, A. E., Pitta, D., Hennessy, M. L., Indugu, N., Vecchiarelli, B., Luethy, D., Aceto, H. W., & Hurcombe, S. D. A. (2024) · Figshare · doi:10.6084/m9.figshare.26747489
Langdon, A. E., Schwartz, D. J., Bulow, C., Sun, X., Hink, T., Reske, K. A., Jones, C. R., Burnham, C.-A. D., Dubberke, E. R., & Dantas, G. (2021) · Figshare · doi:10.6084/m9.figshare.14052702
Langdon, A. E., Schwartz, D. J., Bulow, C., Sun, X., Hink, T., Reske, K. A., Jones, C. R., Burnham, C.-A. D., Dubberke, E. R., & Dantas, G. (2021) · Figshare · doi:10.6084/m9.figshare.14052684
Long, A. E., Pitta, D., Hennessy, M. L., Indugu, N., Vecchiarelli, B., Luethy, D., Aceto, H. W., & Hurcombe, S. D. A. (2024) · Figshare · doi:10.6084/m9.figshare.26747495
Wilson, B. C., Vatanen, T., Jayasinghe, T. N., Leong, K. S. W., Derraik, J. G., Albert, B. B., Chiavaroli, V., Svirskis, D. M., Beck, K. L., Conlon, C. A., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14594454
Long, A. E., Pitta, D., Hennessy, M. L., Indugu, N., Vecchiarelli, B., Luethy, D., Aceto, H. W., & Hurcombe, S. D. A. (2024) · Figshare · doi:10.6084/m9.figshare.26747504
Long, A. E., Pitta, D., Hennessy, M. L., Indugu, N., Vecchiarelli, B., Luethy, D., Aceto, H. W., & Hurcombe, S. D. A. (2024) · Figshare · doi:10.6084/m9.figshare.26241184
Lewis, B. (2017) · eCommons (Cornell University)
Vincent, C. (2016) · eScholarship@McGill (McGill) · doi:10.82308/21751
Optimisation de la viabilité bactérienne pour la transplantation de microbiote fécal chez le chien
Ratté, M. (2022) · Papyrus : Institutional Repository (Université de Montréal) · doi:10.71781/3970
Mårtens, E. (2020) · Theseus (Ammattikorkeakoulujen)
Kular, J., Malec, O., Michalska, I., Karwat, M., Myśliwiec, M., Niebylecka, J., Glanc, N., Tyralik, T., Zalewski, G., & Sendecki, D. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(47).2025.3752
Faust, K. (2016) · VUBIR (Vrije Universiteit Brussel)
Therapeutic options for Clostridioides difficile infections
Balázs, V. A. (2023) · Pesci Egyetemi Archivum (University of Pécs)
Implementing microbiome analysis in clinical practice
Tiwari, S. N., Kumar, S. D., Kumar, M., Kumar, S. K., & Gupta, P. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-40483-2.00046-7
George, M., Negi, L., & Maan, M. (2026) · Gastroenterology Nursing · doi:10.1097/sga.0000000000000961
Moser, K., Ballif, A., Becker, D., Carrez, L., Audry, M., Gerber, S., & Galpérine, T. (2026) · Swiss Medical Weekly · doi:10.57187/5144
Zhang, Z.-Y., Li, Z.-D., Peng, C.-W., Peng, H., Zou, X., Yuan-xia, Z., Liao, W.-L., Tian-ke, L., & Li, R. H. (2026) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848261467814
Hasanuzzaman, M., Bang, C. S., Lee, J. J., & Gong, E. J. (2026) · Journal of Korean Medical Science · doi:10.3346/jkms.2026.41.e335
Antibiotic-induced disruption in gut microbiome and its connection to human diseases
Kumpulainen, L. (2025) · UEF eRepo (University of Eastern Finland)
Bilinski, J., Dziurzynski, M., Grzesiowski, P., Podsiadly, E., Stelmaszczyk-Emmel, A., Dzieciatkowski, T., Lis, K., Tyszka, M., Ozieranski, K., Dziewit, Ł., et al. (2022) · doi:10.3389/fmicb.2022.872735.s001
Bacteriotherapy reintroduces “old friends” in IBD
Nanki, K., Naganuma, M., Mizuno, S., Matsuoka, K., & Kanai∥, T. (2015) · Inflammation and Regeneration · doi:10.2492/inflammregen.35.122
Metadata
- Authors
- Youngster, I., Sauk, J., Pindar, C., Wilson, R. G., Kaplan, J. L., Smith, M. B., Alm, E. J., Gevers, D., Russell, G. H., & Hohmann, E. L.
- Affiliations
- Boston Children's Hospital (US)
- Harvard University (US)
- Massachusetts General Hospital (US)
- Broad Institute (US)
- Corresponding author
- Youngster, Ilan
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-04-23
- Volume
- 58
- Issue
- 11
- Pages
- 1515-1522
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- PMC
- PMC4017893
- OpenAlex
- W2146116383
- Cited by
- 467
- References
- 32
- Citations by year
- 2026: 7 · 2025: 15 · 2024: 31 · 2023: 22 · 2022: 24 · 2021: 35 · 2020: 37 · 2019: 51 · 2018: 47 · 2017: 57 · 2016: 53 · 2015: 61 · 2014: 27
- FWCI
- 46.23
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinical Infectious Diseases (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc-sa)
- Funders
- National Institutes of Health (UL1TR000170)
- National Institute of Allergy and Infectious Diseases (HHSN272200900018C)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK043351)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Infectious Diseases › Clostridium difficile and Clostridium perfringens research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- fecal microbiota transplantation, recurrent Clostridium difficile infection, unrelated donor, nasogastric tube administration, diarrhea resolution, health-related quality of life, antibiotic-refractory infection
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Biological Therapy, Child, Clostridium Infections, Colonoscopy, Diarrhea, Female, Humans, Intubation, Gastrointestinal, Male, Middle Aged, Pilot Projects, Surveys and Questionnaires, Recurrence, Clostridioides difficile, Treatment Outcome, Young Adult, Unrelated Donors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.